Related references
Note: Only part of the references are listed.Glucocorticoid-induced osteoporosis: 2019 concise clinical review
G. Adami et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Glucocorticoid-induced osteoporosis update
Giovanni Adami et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
Kenneth G. Saag et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
M. Kamimura et al.
OSTEOPOROSIS INTERNATIONAL (2017)
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Lenore Buckley et al.
ARTHRITIS & RHEUMATOLOGY (2017)
The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease
Shigeo Ishiguro et al.
ARCHIVES OF OSTEOPOROSIS (2017)
UK clinical guideline for the prevention and treatment of osteoporosis
J. Compston et al.
ARCHIVES OF OSTEOPOROSIS (2017)
Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study
J. N. Tsai et al.
BONE (2017)
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
Yasuo Suzuki et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2014)
Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
Toshitaka Nakamura et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis
E. Cairoli et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence
John S. Sampalis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Effects of Denosumab on Bone Turnover Markers in Postmenopausal Osteoporosis
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Influence of glucocorticoids on human osteoclast generation and activity
S Sivagurunathan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
PJ Bekker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
TP Van Staa et al.
ARTHRITIS AND RHEUMATISM (2003)
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis
NH Bjarnason et al.
OSTEOPOROSIS INTERNATIONAL (2001)
Share Paper
